Open AccessSafety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
Author(s) -
Vineet Talwar,
Sharanabasappa Somanath Nirni,
Krishna Mohan Mallavarapu,
Anupama Ramkumar,
Nitu Sinha
Publication year - 2017
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/2278-330x.202560
Subject(s) - medicine , pegfilgrastim , febrile neutropenia , neutropenia , tolerability , adverse effect , vomiting , nausea , chemotherapy , surgery
A granulocyte colony-stimulating factor, pegfilgrastim, is efficacious though expensive for prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia. Biologics available and accessible today, having acceptable safety-efficacy profiles, require postapproval studies for better understanding of such drugs in clinical settings.